Friday, 6 November 2026European Markets

HOLLAND COLOURS And IMCD Have A High Dividend Yield And Return On Equity In The Specialty Chemicals Industry.

Loading stream...

(VIANEWS) - HOLLAND COLOURS (HOLCO.AS) is among this list of stock assets with the highest dividend rate and return on equity on the Specialty Chemicals industry.

Financial Asset Price Forward Dividend Yield Return on Equity
HOLLAND COLOURS (HOLCO.AS) €90.00 3.9% 6.75%
IMCD (IMCD.AS) €149.50 1.5% 17.66%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. HOLLAND COLOURS (HOLCO.AS)

3.9% Forward Dividend Yield and 6.75% Return On Equity

Holland Colours N.V., together with its subsidiaries, manufactures, distributes, and sells color concentrates in Europe, the Middle East, India, Africa, the Americas, and Asia. The company offers colorants for the building and construction industry, including profiles, pipes, tubing and fittings, siding and cladding, decking, fencing, window blinds, and insulation, as well as solutions for a range of polymers. It also provides colorants for packaging applications comprising water, carbonated soft drinks, fruit juices, dairy, beer, wine, detergents, pharmaceutical, and personal care products. In addition, the company offers coatings, sealants, or adhesives; and colorants for other markets, such as shopping bags, polybags, mulch films, OPP tapes, PU flexible foams, synthetic leather, fiber glass and buttons, paving blocks, artificial stones, cast PMMA, PP non-woven and spunbond, coatings, flexible PVCs, prosthetics, glass fiber reinforced nylon, and silicone rubber and elastomers. It sells its products through a network of agents and distributors. The company was founded in 1979 and is headquartered in Apeldoorn, the Netherlands. Holland Colours N.V. is a subsidiary of Holland Pigments BV.

Earnings Per Share

As for profitability, HOLLAND COLOURS has a trailing twelve months EPS of €4.68.

PE Ratio

HOLLAND COLOURS has a trailing twelve months price to earnings ratio of 19.23. Meaning, the purchaser of the share is investing €19.23 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.75%.

Yearly Top and Bottom Value

HOLLAND COLOURS's stock is valued at €90.00 at 06:40 EST, way below its 52-week high of €132.00 and higher than its 52-week low of €82.00.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jul 17, 2023, the estimated forward annual dividend rate is 3.41 and the estimated forward annual dividend yield is 3.9%.

Volatility

HOLLAND COLOURS's last week, last month's, and last quarter's current intraday variation average was 0.76%, 0.42%, and 2.22%.

HOLLAND COLOURS's highest amplitude of average volatility was 0.76% (last week), 1.74% (last month), and 2.22% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HOLLAND COLOURS's stock is considered to be oversold (<=20).

More news about HOLLAND COLOURS.

2. IMCD (IMCD.AS)

1.5% Forward Dividend Yield and 17.66% Return On Equity

IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers bioactives, biocides, chelates, functional additives, rheology modifiers, silicones, solubilisers, and solvents; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, binders, corrosion inhibitors, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, IMCD has a trailing twelve months EPS of €5.07.

PE Ratio

IMCD has a trailing twelve months price to earnings ratio of 29.49. Meaning, the purchaser of the share is investing €29.49 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.66%.

Yearly Top and Bottom Value

IMCD's stock is valued at €149.50 at 06:40 EST, under its 52-week high of €158.40 and way above its 52-week low of €109.05.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.3%, now sitting on 4.59B for the twelve trailing months.

More news about IMCD.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com